Stock MIRM MIRUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
24.46 USD -0.12% Intraday chart for Mirum Pharmaceuticals, Inc. +2.73% -17.14%
04-17 Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target MT
04-02 Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome CI

Business Summary

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Number of employees: 264

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Therapies
100.0 %
77 100.0 % 186 100.0 % +141.85%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
82.0 %
77 100.0 % 147 82.0 % +90.36%
Rest of World
18.0 %
-- 32 18.0 % -

Managers

Managers TitleAgeSince
Christopher Peetz FOU
 Founder 45 06/05/18
Michael Grey FOU
 Founder 71 06/05/18
Peter Radovich PSD
 President 46 27/04/20
Eric Bjerkholt DFI
 Director of Finance/CFO 64 10/09/23
Pamela Vig CTO
 Chief Tech/Sci/R&D Officer 53 30/11/18
Joanne Quan CTO
 Chief Tech/Sci/R&D Officer 60 01-15
Paul K. Ross CMP
 Compliance Officer - 31/03/20
Andrew McKibben IRC
 Investor Relations Contact - -
Erin Campany HRO
 Human Resources Officer 57 31/12/21
Lara Krupka-Longpre PRN
 Corporate Officer/Principal 54 30/11/18

Members of the board

Members of the board TitleAgeSince
Timothy Walbert BRD
 Director/Board Member 57 04/04/23
Michael Grey FOU
 Founder 71 06/05/18
Patrick Heron BRD
 Director/Board Member 53 06/11/18
Laurent Fischer BRD
 Director/Board Member 60 31/05/19
Laura Brege BRD
 Director/Board Member 66 16/07/19
Sona Saira Ramasastry BRD
 Director/Board Member 48 01/06/22
Christopher Peetz FOU
 Founder 45 06/05/18
Lon Cardon BRD
 Director/Board Member - 18/12/22
William Fairey BRD
 Director/Board Member 59 18/08/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 47,118,397 45,175,854 ( 95.88 %) 0 95.88 %

Shareholders

NameEquities%Valuation
Frazier Life Sciences Management LP
13.93 %
6,495,392 13.93 % 163 M $
BVF, Inc.
9.375 %
4,370,024 9.375 % 110 M $
Eventide Asset Management LLC
5.714 %
2,663,649 5.714 % 67 M $
Vanguard Fiduciary Trust Co.
5.312 %
2,476,244 5.312 % 62 M $
BlackRock Advisors LLC
5.040 %
2,349,532 5.040 % 59 M $
Janus Henderson Investors US LLC
4.425 %
2,062,551 4.425 % 52 M $
Cadian Capital Management LP
4.151 %
1,934,922 4.151 % 49 M $
Rock Springs Capital Management LP
3.972 %
1,851,464 3.972 % 47 M $
STATE STREET CORPORATION
3.722 %
1,734,775 3.722 % 44 M $
Novo Holdings A/S (Investment Company)
3.218 %
1,500,000 3.218 % 38 M $

Company contact information

Mirum Pharmaceuticals, Inc.

950 Tower Lane Suite 1050

94404, Foster City

+650 667 4085

http://www.mirumpharma.com
address Mirum Pharmaceuticals, Inc.(MIRM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for Mirum Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
24.46 USD
Average target price
48.91 USD
Spread / Average Target
+99.96%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MIRUM PHARMACEUTICALS, INC. Stock Mirum Pharmaceuticals, Inc.
-17.14% 1.15B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+48.04% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MIRM Stock
  4. Company Mirum Pharmaceuticals, Inc.